Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy

(2015) M. Joerger et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Two-stage designs in bioequivalence trials

(2015) Helmut Schütz   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

(2013) A Loganayagam et al.   BRITISH JOURNAL OF CANCER

Bioequivalence study designs for generic solid oral anticancer drug products: Scientific and regulatory considerations

(2013) Paramjeet Kaur et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer

(2012) Siddharth Chachad et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Plasma disposition of capecitabine and its metabolites 5′DFCR and 5′DFUR in a standard and dose-intensified monotherapy regimen

(2010) Martin Czejka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population

(2009) Francesco M. Carpi et al.   MOLECULAR BIOLOGY REPORTS

Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study

(2008) L. Chaigneau et al.   ANNALS OF ONCOLOGY

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY